Niklas Mattsson

List of Publications by Year
in descending order

283 papers	24,394 citations	8172 76 h-index	9334 143 g-index
311 all docs	311 docs citations	311 times ranked	17827 citing authors

#	Article	IF	Citations
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
2	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 385.	3.8	1,009
3	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurology, The, 2020, 19, 422-433.	4.9	668
4	Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurology, 2017, 74, 557.	4.5	664
5	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nature Medicine, 2020, 26, 379-386.	15.2	643
6	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2020, 324, 772.	3.8	640
7	Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nature Communications, 2017, 8, 1214.	5.8	596
8	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676.	4.9	464
9	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
10	Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurology, 2019, 76, 791.	4.5	436
11	Amyloid biomarkers in Alzheimer's disease. Trends in Pharmacological Sciences, 2015, 36, 297-309.	4.0	404
12	Plasma tau in Alzheimer disease. Neurology, 2016, 87, 1827-1835.	1.5	371
13	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.4	354
14	Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurology, 2016, 73, 60.	4.5	354
15	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
16	CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Annals of Clinical and Translational Neurology, 2016, 3, 154-165.	1.7	329
17	Discriminative Accuracy of [^{18}F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2018, 320, 1151.	3.8	298
18	Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain, 2016, 139, 1226-1236.	3.7	292

#	Article	IF	Citations
19	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology, 2015, 85, 1240-1249.	1.5	288
20	Smoking and increased Alzheimer's disease risk: A review of potential mechanisms. Alzheimer's and Dementia, 2014, 10, S122-45.	0.4	285
21	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status. JAMA Neurology, 2019, 76, 1060.	4.5	282
22	Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Scientific Reports, 2016, 6, 36791.	1.6	281
23	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. Nature Communications, 2020, 11, 1683.	5.8	252
24	The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713.	0.4	249
25	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. Nature Medicine, 2021, 27, 1034-1042.	15.2	236
26	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. EMBO Molecular Medicine, 2019, 11, e11170.	3.3	228
27	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurology, The, 2021, 20, 739-752.	4.9	220
28	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Molecular Medicine, 2016, 8, 1184-1196.	3.3	219
29	CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology, 2014, 83, 1945-1953.	1.5	213
30	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology, 2018, 91, e867-e877.	1.5	207
31	Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. Science Advances, 2020, 6, eaaz2387.	4.7	202
32	Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease. Brain, 2015, 138, 772-783.	3.7	200
33	Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. Brain, 2015, 138, 3373-3385.	3.7	200
34	Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. Brain, 2021, 144, 3505-3516.	3.7	198
35	Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology, 2019, 92, e601-e612.	1.5	196
36	Reporting standards for studies of diagnostic test accuracy in dementia. Neurology, 2014, 83, 364-373.	1.5	182

#	Article	IF	Citations
37	Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurology, 2021, 78, 149.	4.5	176
38	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1145-1156.	0.4	174
39	Diagnostic Performance of Cerebrospinal Fluid Total Tau and Phosphorylated Tau in Creutzfeldt-Jakob Disease. JAMA Neurology, 2014, 71, 476.	4.5	164
40	Biomarkers for tau pathology. Molecular and Cellular Neurosciences, 2019, 97, 18-33.	1.0	163
41	Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest. JAMA Neurology, 2019, 76, 64.	4.5	158
42	¹⁸Fâ€AVâ€1451 and CSF Tâ€tau and Pâ€tau as biomarkers in Alzheimer's disease. EMBO Molecular Medicine, 2017, 9, 1212-1223.	3.3	156
43	Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Alimentary Pharmacology and Therapeutics, 2006, 24, 945-954.	1.9	155
44	Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology, 2012, 78, 468-476.	1.5	154
45	Cerebrospinal fluid tau and amyloid-β$_{1-42}$ in patients with dementia. Brain, 2015, 138, 2716-2731.	3.7	152
46	Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. Brain, 2014, 137, 1550-1561.	3.7	150
47	Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. Brain, 2020, 143, 3234-3241.	3.7	150
48	Staging **β**-Amyloid Pathology With Amyloid Positron Emission Tomography. JAMA Neurology, 2019, 76, 1319.	4.5	149
49	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	4.5	148
50	Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease. Acta Neuropathologica Communications, 2019, 7, 169.	2.4	146
51	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimer's and Dementia, 2015, 11, 740-756.	0.4	142
52	Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. JAMA Neurology, 2020, 77, 955.	4.5	136
53	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
54	Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	2.8	132

#	Article	IF	Citations
55	Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays. Scientific Reports, 2019, 9, 19024.	1.6	123
56	Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease. Brain, 2021, 144, 310-324.	3.7	123
57	Blood-based biomarkers for Alzheimer's disease. EMBO Molecular Medicine, 2022, 14, e14408.	3.3	122
58	Intra-Individual Stability of CSF Biomarkers for Alzheimer's Disease over Two Years. Journal of Alzheimer's Disease, 2007, 12, 255-260.	1.2	117
59	Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimer's Research and Therapy, 2021, 13, 68.	3.0	117
60	Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nature Communications, 2021, 12, 3555.	5.8	115
61	Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimer's and Dementia, 2013, 9, 137-140.	0.4	105
62	Cerebrospinal Fluid Microglial Markers in Alzheimer's Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility. NeuroMolecular Medicine, 2011, 13, 151-159.	1.8	104
63	CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. Alzheimer's and Dementia, 2015, 11, 1306-1315.	0.4	104
64	Apathy and anxiety are early markers of Alzheimer's disease. Neurobiology of Aging, 2020, 85, 74-82.	1.5	103
65	Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 196-213.	1.5	100
66	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. Alzheimer's and Dementia, 2018, 14, 563-575.	0.4	98
67	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
68	Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease. Annals of Clinical and Translational Neurology, 2014, 1, 534-543.	1.7	96
69	Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology, 2019, 93, e322-e333.	1.5	96
70	Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 83-91.	1.8	94
71	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nature Aging, 2021, 1, 114-123.	5.3	94
72	Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Molecular Medicine, 2021, 13, e14022.	3.3	90

#	ARTICLE	IF	CITATIONS
73	Lysosomal Network Proteins as Potential Novel CSF Biomarkers for Alzheimer's Disease. NeuroMolecular Medicine, 2014, 16, 150-160.	1.8	89
74	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. Alzheimer's and Dementia, 2018, 14, 1313-1333.	0.4	87
75	Serum tau and neurological outcome in cardiac arrest. Annals of Neurology, 2017, 82, 665-675.	2.8	86
76	Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. JAMA Psychiatry, 2014, 71, 1183.	6.0	85
77	CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. Neurobiology of Aging, 2017, 59, 1-9.	1.5	84
78	Predicting diagnosis and cognition with [18]F‑AV‑1451 tau PET and structural MRI in Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 570-580.	0.4	84
79	Comparing ^{18}F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. Neurology, 2018, 90, e388-e395.	1.5	83
80	Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 412-419.	1.2	80
81	The implications of different approaches to define AT(N) in Alzheimer disease. Neurology, 2020, 94, e2233-e2244.	1.5	80
82	Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clinical Chemistry and Laboratory Medicine, 2010, 48, 603-607.	1.4	78
83	An online nano‑LC‑ESI‑FTICR‑MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid. Journal of Mass Spectrometry, 2012, 47, 591-603.	0.7	78
84	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease. Translational Psychiatry, 2021, 11, 76.	2.4	78
85	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. Brain, 2021, 144, 2771-2783.	3.7	78
86	Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2012, 30, 767-778.	1.2	76
87	Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42. Biomarkers in Medicine, 2012, 6, 409-417.	0.6	76
88	Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 2011, 3, 1.	1.7	73
89	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‑tau. Alzheimer's and Dementia, 2022, 18, 283-293.	0.4	72
90	Cerebrospinal Fluid Profiles of Amyloid β-Related Biomarkers in Alzheimer's Disease. NeuroMolecular Medicine, 2012, 14, 65-73.	1.8	70

#	Article	IF	Citations
91	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population. Journal of Alzheimer's Disease, 2011, 24, 537-546.	1.2	68
92	Bidirectional links between Alzheimer's disease and Niemann–Pick type C disease. Neurobiology of Disease, 2014, 72, 37-47.	2.1	68
93	BACE1 Inhibition Induces a Specific Cerebrospinal Fluid β-Amyloid Pattern That Identifies Drug Effects in the Central Nervous System. PLoS ONE, 2012, 7, e31084.	1.1	68
94	Novel AβIsoforms in Alzheimer's Disease - Their Role in Diagnosis and Treatment. Current Pharmaceutical Design, 2011, 17, 2594-2602.	0.9	66
95	Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. Psychoneuroendocrinology, 2013, 38, 1729-1737.	1.3	66
96	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurology, 2022, 79, 149.	4.5	66
97	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain, 2021, 144, 2826-2836.	3.7	65
98	The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Brain, 2020, 143, 3805-3815.	3.7	65
99	γ-Secretase-dependent amyloid-β is increased in Niemann-Pick type C. Neurology, 2011, 76, 366-372.	1.5	62
100	Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1000-1004.	0.9	62
101	Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. Frontiers in Neuroscience, 2017, 11, 281.	1.4	62
102	CSF Biomarkers. Annals of the New York Academy of Sciences, 2009, 1180, 28-35.	1.8	60
103	Assessment of Peptide Chemical Modifications on the Development of an Accurate and Precise Multiplex Selected Reaction Monitoring Assay for Apolipoprotein E Isoforms. Journal of Proteome Research, 2014, 13, 1077-1087.	1.8	60
104	Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia. American Journal of Geriatric Psychiatry, 2016, 24, 126-135.	0.6	60
105	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. Neurology, 2021, 97, e1681-e1694.	1.5	60
106	Performance of a guideline-recommended algorithm for prognostication of poor neurological outcome after cardiac arrest. Intensive Care Medicine, 2020, 46, 1852-1862.	3.9	59
107	Cerebrospinal fluid neurofilament light concentration in motor neuron disease and frontotemporal dementia predicts survival. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 397-403.	1.1	58
108	Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58

#	Article	IF	Citations
109	Tau PET correlates with different Alzheimer's disease–related features compared to CSF and plasma p–tau biomarkers. EMBO Molecular Medicine, 2021, 13, e14398.	3.3	58
110	Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS. PLoS ONE, 2012, 7, e42555.	1.1	57
111	CSF biomarkers in neurodegenerative diseases. Clinical Chemistry and Laboratory Medicine, 2011, 49, 345-352.	1.4	56
112	Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer's disease: a cohort study. Alzheimer's Research and Therapy, 2018, 10, 77.	3.0	56
113	Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 448-454.	1.4	55
114	Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease. Neurology, 2021, 96, e193-e202.	1.5	54
115	Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. Current Opinion in Neurology, 2021, 34, 266-274.	1.8	54
116	Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges. Biomarkers in Medicine, 2012, 6, 391-400.	0.6	52
117	CSF protein biomarkers predicting longitudinal reduction of CSF β-amyloid42 in cognitively healthy elders. Translational Psychiatry, 2013, 3, e293-e293.	2.4	51
118	Emerging β-Amyloid Pathology and Accelerated Cortical Atrophy. JAMA Neurology, 2014, 71, 725.	4.5	51
119	Serum markers of brain injury can predict good neurological outcome after out-of-hospital cardiac arrest. Intensive Care Medicine, 2021, 47, 984-994.	3.9	50
120	Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. BMC Neurology, 2010, 10, 51.	0.8	49
121	Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection. BMC Neurology, 2013, 13, 2.	0.8	49
122	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2340-2347.	1.5	49
123	Assessing risk for preclinical β–amyloid pathology with <i>APOE</i>, cognitive, and demographic information. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 76-84.	1.2	49
124	Accurate risk estimation of β–amyloid positivity to identify prodromal Alzheimer's disease: Cross–validation study of practical algorithms. Alzheimer's and Dementia, 2019, 15, 194-204.	0.4	49
125	Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. Neurology, 2022, 98, .	1.5	49
126	To Know or Not to Know: Ethical Issues Related to Early Diagnosis of Alzheimer's Disease. International Journal of Alzheimer's Disease, 2010, 2010, 1-4.	1.1	48

#	Article	IF	Citations
127	Mass Spectrometric Characterization of Amyloid-β Species in the 7PA2 Cell Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, 85-93.	1.2	48
128	Increased amyloidogenic APP processing in APOE É›4-negative individuals with cerebral β-amyloidosis. Nature Communications, 2016, 7, 10918.	5.8	48
129	Understanding the cause of sporadic Alzheimer's disease. Expert Review of Neurotherapeutics, 2014, 14, 621-630.	1.4	47
130	Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease. PLoS ONE, 2013, 8, e81989.	1.1	45
131	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. Scientific Reports, 2017, 7, 13333.	1.6	45
132	Leukocyte Telomere Length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's Disease: A pilot study. Experimental Gerontology, 2012, 47, 179-182.	1.2	44
133	Exploring Alzheimer Molecular Pathology in Down's Syndrome Cerebrospinal Fluid. Neurodegenerative Diseases, 2014, 14, 98-106.	0.8	44
134	Brain structure and function as mediators of the effects of amyloid on memory. Neurology, 2015, 84, 1136-1144.	1.5	44
135	Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 543-552.	1.4	43
136	The A4 study: *β*-amyloid and cognition in 4432 cognitively unimpaired adults. Annals of Clinical and Translational Neurology, 2020, 7, 776-785.	1.7	43
137	Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults. Neurobiology of Aging, 2014, 35, 614-622.	1.5	42
138	Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls. JAMA Neurology, 2015, 72, 554.	4.5	42
139	Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology. Neurology, 2016, 86, 1887-1896.	1.5	42
140	Relevance of biomarkers across different neurodegenerative diseases. Alzheimer's Research and Therapy, 2020, 12, 56.	3.0	42
141	A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2295-2305.	3.3	41
142	Amyloid-β metabolism in Niemann-Pick C disease models and patients. Metabolic Brain Disease, 2012, 27, 573-585.	1.4	39
143	Proteomic profiling of cerebrospinal fluid in parkinsonian disorders. Parkinsonism and Related Disorders, 2010, 16, 545-549.	1.1	38
144	Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease. Psychoneuroendocrinology, 2013, 38, 1058-1066.	1.3	38

#	Article	IF	Citations
145	Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage?. Clinical Chemistry and Laboratory Medicine, 2013, 51, 2073-2086.	1.4	37
146	Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples. Alzheimer's Research and Therapy, 2013, 5, 47.	3.0	37
147	The transitional association between Î²â€‹amyloid pathology and regional brain atrophy. Alzheimer's and Dementia, 2015, 11, 1171-1179.	0.4	37
148	Serum GFAP and UCH-L1 for the prediction of neurological outcome in comatose cardiac arrest patients. Resuscitation, 2020, 154, 61-68.	1.3	37
149	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. Nature Communications, 2020, 11, 6252.	5.8	36
150	Converging molecular pathways in human neural development and degeneration. Neuroscience Research, 2010, 66, 330-332.	1.0	34
151	Elevated cerebrospinal fluid F2-isoprostane levels indicating oxidative stress in healthy siblings of multiple sclerosis patients. Neuroscience Letters, 2007, 414, 233-236.	1.0	33
152	Cerebrospinal Fluid Brain Injury Biomarkers in Children: A Multicenter Study. Pediatric Neurology, 2013, 49, 31-39.e2.	1.0	33
153	Associations between partial pressure of oxygen and neurological outcome in out-of-hospital cardiac arrest patients: an explorative analysis of a randomized trial. Critical Care, 2019, 23, 30.	2.5	33
154	Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2015, 2, 534-547.	1.7	32
155	Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases courseâ€"a joint PhD student course at University College London and University of Gothenburg. Alzheimer's Research and Therapy, 2020, 12, 20.	3.0	32
156	Î²-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces AÎ²5-X peptides through alternative amyloid precursor protein cleavage. Alzheimer's Research and Therapy, 2014, 6, 75.	3.0	31
157	Carbon dioxide dynamics in relation to neurological outcome in resuscitated out-of-hospital cardiac arrest patients: an exploratory Target Temperature Management Trial substudy. Critical Care, 2018, 22, 196.	2.5	31
158	The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis. Journal of Neuroimmunology, 2013, 264, 100-105.	1.1	30
159	CSF biomarkers for Alzheimerâ€™s pathology and the effect size of APOE É›4. Molecular Psychiatry, 2014, 19, 148-149.	4.1	30
160	Interaction of Cigarette Smoking History With<i>APOE</i>Genotype and Age on Amyloid Level, Glucose Metabolism, and Neurocognition in Cognitively Normal Elders. Nicotine and Tobacco Research, 2016, 18, 204-211.	1.4	30
161	Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. Journal of Neurochemistry, 2007, 103, 1932-1939.	2.1	29
162	Elevated cerebrospinal fluid levels of prostaglandin E2 and 15<i>â€‹(S)â€‹</i>hydroxyeicosatetraenoic acid in multiple sclerosis. Journal of Internal Medicine, 2009, 265, 459-464.	2.7	28

#	Article	IF	Citations
163	Altered Cerebrospinal Fluid Levels of Amyloid β and Amyloid Precursor-Like Protein 1 Peptides in Down's Syndrome. NeuroMolecular Medicine, 2014, 16, 510-516.	1.8	28
164	Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment. Neurobiology of Aging, 2016, 48, 172-181.	1.5	28
165	β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. Scientific Reports, 2019, 9, 11180.	1.6	28
166	Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment. JAMA Neurology, 2021, 78, 229.	4.5	28
167	Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition. Scientific Reports, 2021, 11, 1965.	1.6	28
168	Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease. International Journal of Alzheimer's Disease, 2010, 2010, 1-5.	1.1	27
169	Cerebrospinal Fluid α-Synuclein and Lewy Body-Like Symptoms in Normal Controls, Mild Cognitive Impairment, and Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 1007-1016.	1.2	27
170	Amyloid pathology in the progression to mild cognitive impairment. Neurobiology of Aging, 2018, 64, 76-84.	1.5	27
171	Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. Human Brain Mapping, 2019, 40, 638-651.	1.9	27
172	Comparing progression biomarkers in clinical trials of early Alzheimer's disease. Annals of Clinical and Translational Neurology, 2020, 7, 1661-1673.	1.7	27
173	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	3.3	27
174	Novel cerebrospinal fluid biomarkers of axonal degeneration in frontotemporal dementia. Molecular Medicine Reports, 2008, 1, 757-61.	1.1	26
175	Cortical Atrophy is Associated with Accelerated Cognitive Decline in Mild Cognitive Impairment with Subsyndromal Depression. American Journal of Geriatric Psychiatry, 2017, 25, 980-991.	0.6	26
176	Miglustat Treatment May Reduce Cerebrospinal Fluid Levels of the Axonal Degeneration Marker Tau in Niemann-Pick Type C. JIMD Reports, 2011, 3, 45-52.	0.7	25
177	History of cigarette smoking in cognitively-normal elders is associated with elevated cerebrospinal fluid biomarkers of oxidative stress. Drug and Alcohol Dependence, 2014, 142, 262-268.	1.6	25
178	Serum visinin-like protein-1 in concussed professional ice hockey players. Brain Injury, 2015, 29, 872-876.	0.6	25
179	Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2021, 8, 259-265.	1.7	25
180	Preoperative sleep quality and adverse pain outcomes after total hip arthroplasty. European Journal of Pain, 2021, 25, 1482-1492.	1.4	25

#	ARTICLE	IF	CITATIONS
181	Alzheimer's disease and CSF biomarkers: key challenges for broad clinical applications. Biomarkers in Medicine, 2009, 3, 735-737.	0.6	24
182	Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers. Biomarkers in Medicine, 2012, 6, 401-407.	0.6	24
183	The <i>BIN1</i> rs744373 Alzheimer's disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline. Alzheimer's and Dementia, 2022, 18, 103-115.	0.4	24
184	Biomarkers for Microglial Activation in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2011, 2011, 1-5.	1.1	23
185	Automated cerebrospinal fluid cell count — New reference ranges and evaluation of its clinical use in central nervous system infections. Clinical Biochemistry, 2014, 47, 25-30.	0.8	22
186	Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations. Alzheimer's Research and Therapy, 2017, 9, 87.	3.0	22
187	Cerebrospinal Fluid Levels of Neurogranin in Parkinsonian Disorders. Movement Disorders, 2020, 35, 513-518.	2.2	22
188	Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition. Neurology, 2022, 98, .	1.5	22
189	Cerebrospinal fluid biomarkers of β-amyloid metabolism and neuronal damage in epileptic seizures. European Journal of Neurology, 2014, 21, 486-491.	1.7	21
190	Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer's Disease Pathology and Cognitive Decline. Biological Psychiatry, 2022, 92, 34-43.	0.7	21
191	Time between milestone events in the Alzheimer's disease amyloid cascade. NeuroImage, 2021, 227, 117676.	2.1	20
192	Converging Pathways of Chromogranin and Amyloid Metabolism in the Brain. Journal of Alzheimer's Disease, 2010, 20, 1039-1049.	1.2	19
193	CSF in Alzheimer's Disease. Advances in Clinical Chemistry, 2014, 65, 143-172.	1.8	19
194	Cerebrospinal fluid biomarkers in neurological diseases in children. European Journal of Paediatric Neurology, 2013, 17, 7-13.	0.7	18
195	Serum levels of LIGHT in MS. Multiple Sclerosis Journal, 2013, 19, 871-876.	1.4	17
196	Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem. Alzheimer's and Dementia, 2015, 11, 1470-1479.	0.4	17
197	Total-tau and neurofilament light in CSF reflect spinal cord ischaemia after endovascular aortic repair. Neurochemistry International, 2016, 93, 1-5.	1.9	17
198	Ex vivo 18O-labeling mass spectrometry identifies a peripheral amyloid β clearance pathway. Molecular Neurodegeneration, 2017, 12, 18.	4.4	17

#	Article	IF	Citations
199	CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in APOE ε4 carriers. Scientific Reports, 2020, 10, 8233.	1.6	17
200	Future Screening for Incipient Alzheimer's Disease – The Influence of Prevalence on Test Performance. European Neurology, 2009, 62, 200-203.	0.6	16
201	Effects of Baseline CSF α-Synuclein on Regional Brain Atrophy Rates in Healthy Elders, Mild Cognitive Impairment and Alzheimer's Disease. PLoS ONE, 2013, 8, e85443.	1.1	16
202	Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment. International Journal of Geriatric Psychiatry, 2018, 33, 1305-1311.	1.3	16
203	Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12099.	1.2	16
204	Association of CSF Aβ_{38} Levels With Risk of Alzheimer Disease–Related Decline. Neurology, 2022, 98, .	1.5	16
205	Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease. Alzheimer's Research and Therapy, 2010, 2, 32.	3.0	15
206	Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer's disease, and neuronal injury in humans: a cohort study. Journal of Neuroinflammation, 2017, 14, 193.	3.1	15
207	Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. Neurobiology of Aging, 2018, 71, 81-90.	1.5	15
208	Biochemical markers in Alzheimer's disease clinical trials. Biomarkers in Medicine, 2010, 4, 91-98.	0.6	14
209	Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease: Long-Term Observation and Implications of Clinical Subtypes. Journal of Parkinson's Disease, 2022, 12, 571-584.	1.5	13
210	The N-terminal domain of α-dystroglycan, released as a 38kDa protein, is increased in cerebrospinal fluid in patients with Lyme neuroborreliosis. Biochemical and Biophysical Research Communications, 2011, 412, 494-499.	1.0	11
211	What is a certified reference material?. Biomarkers in Medicine, 2012, 6, 369-370.	0.6	11
212	Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults. Neurobiology of Aging, 2019, 82, 110-119.	1.5	11
213	Differential expression of cerebrospinal fluid neuroinflammatory mediators depending on osteoarthritis pain phenotype. Pain, 2020, 161, 2142-2154.	2.0	11
214	Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women. Clinical Endocrinology, 2011, 75, 301-308.	1.2	10
215	Cerebrospinal fluid neurofilament light is associated with survival in mitochondrial disease patients. Mitochondrion, 2019, 46, 228-235.	1.6	10
216	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2259-2271.	3.3	10

#	Article	IF	Citations
217	The Accu-Chek Mobile blood glucose monitoring system used under controlled conditions meets ISO 15197 standards in the hands of diabetes patients. Scandinavian Journal of Clinical and Laboratory Investigation, 2012, 72, 374-379.	0.6	9
218	Apolipoprotein E genotypes and longevity across dementia disorders. Alzheimer's and Dementia, 2018, 14, 895-901.	0.4	8
219	Predictive Factors of Concerns about Falling in People with Parkinson's Disease: A 3-Year Longitudinal Study. Parkinson's Disease, 2019, 2019, 1-9.	0.6	8
220	The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 683-691.	1.7	8
221	Perceived walking difficulties in Parkinson's disease – predictors and changes over time. BMC Geriatrics, 2021, 21, 221.	1.1	8
222	Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization. Pain Reports, 2022, 7, e988.	1.4	8
223	Components of gait in people with and without mild cognitive impairment. Gait and Posture, 2022, 93, 83-89.	0.6	7
224	Serum neurofilament light levels are correlated to long-term neurocognitive outcome measures after cardiac arrest. Brain Injury, 2022, 36, 800-809.	0.6	7
225	Association Between EEG Patterns and Serum Neurofilament Light After Cardiac Arrest. Neurology, 2022, 98, .	1.5	7
226	Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems. International Journal of Alzheimer's Disease, 2010, 2010, 1-4.	1.1	6
227	Mild behavioral impairment is predictive of tau deposition in the earliest stages of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e042595.	0.4	6
228	Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer's disease. Scientific Reports, 2021, 11, 19853.	1.6	6
229	Reply: Do we still need positron emission tomography for early Alzheimer's disease diagnosis?. Brain, 2016, 139, e61-e61.	3.7	5
230	Cerebrospinal fluid Aβ42/Aβ40 and Aβ42/Aβ38 as biomarkers of Alzheimer's disease. Neurobiology of Aging, 2016, 39, S28.	1.5	5
231	Decreased pain sensitivity and alterations of cerebrospinal fluid and plasma inflammatory mediators after total hip arthroplasty in patients with disabling osteoarthritis. Pain Practice, 2021, , .	0.9	5
232	Astrocytic function is associated with both amyloid-β and tau pathology in non-demented *APOE ε4* carriers. Brain Communications, 2022, 4, .	1.5	4
233	Plasma Amyloid-β in Patients with Tangier Disease. Journal of Alzheimer's Disease, 2013, 35, 307-312.	1.2	3
234	P4-137: THE TRANSITIONAL ASSOCIATION BETWEEN BETA-AMYLOID PATHOLOGY AND REGIONAL BRAIN ATROPHY. , 2014, 10, P837-P838.		3

#	Article	IF	Citations
235	Serum tau fragments as predictors of death or poor neurological outcome after out-of-hospital cardiac arrest. Biomarkers, 2019, 24, 584-591.	0.9	3
236	Acute reduction of cerebrospinal fluid volume prior to spinal anesthesia: implications for sensory block extent. Minerva Anestesiologica, 2020, 86, 636-644.	0.6	3
237	Î²-Amyloidâ€"Dependent and â€"Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease. Neurology, 2022, 99, .	1.5	3
238	Cerebral amyloid burden and Alzheimer's disease subtypes â€" does localization information matter?. European Journal of Neurology, 2016, 23, 233-234.	1.7	2
239	Prediction of future Alzheimerâ€™s disease dementia using plasma phosphoâ€tau combined with other accessible measures. Alzheimer's and Dementia, 2021, 17, .	0.4	2
240	Journal Watch: Our experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. Neurodegenerative Disease Management, 2012, 2, 351-354.	1.2	1
241	Coagulation of cerebrospinal fluidâ€"the Nonneâ€"Froin sign. Practical Neurology, 2013, 13, 273-274.	0.5	1
242	Fluid Biomarkers in Alzheimerâ€™s Disease and Frontotemporal Dementia. , 2018, , 221-252.		1
243	DTâ€02â€04: DETECTING BRAIN AMYLOID STATUS USING FULLY AUTOMATED PLASMA AÎ² BIOMARKER ASSAYS. Alzheimer's and Dementia, 2018, 14, P1670.	0.4	1
244	White matter lesions are associated with CSF biomarkers of neuroinflammation in prodromal Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e041795.	0.4	1
245	Associations between longitudinal neuropsychiatric symptoms and biomarkers of betaâ€amyloid, tau, neurodegeneration, and cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.4	1
246	Research Highlights. Biomarkers in Medicine, 2011, 5, 201-203.	0.6	0
247	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. Neurodegenerative Disease Management, 2012, 2, 451-453.	1.2	0
248	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. Neurodegenerative Disease Management, 2012, 2, 569-572.	1.2	0
249	Cerebrospinal fluid biomarkers to monitor treatment effects in Alzheimerâ€™s disease and related conditions. Neurodegenerative Disease Management, 2012, 2, 117-123.	1.2	0
250	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. Neurodegenerative Disease Management, 2013, 3, 105-107.	1.2	0
251	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management.. Neurodegenerative Disease Management, 2013, 3, 19-21.	1.2	0
252	S5-01-03: CSF biomarkers versus PET biomarkers. , 2015, 11, P302-P302.		0

#	Article	IF	Citations
253	P4â€339: Earlyâ€and Lateâ€Onset Alzheimerâ€™S Disease are Associated with Distinct Regional TAU Pathology as Examined with [18]Fâ€AVâ€1451 TAU Positron Emission Tomography. Alzheimer's and Dementia, 2016, 12, P1164.	0.4	0
254	P2-167: Roadmap to the Biomarker-Based Diagnosis of Alzheimer's Disease. , 2016, 12, P679-P680.		0
255	O1â€05â€01: Increased Amyloidogenic app Processing in Apoe E4â€Negative Individuals with Cerebral Bâ€Amyloidosis. Alzheimer's and Dementia, 2016, 12, P182.	0.4	0
256	ICâ€Pâ€002: : Roadmap to The Biomarkerâ€Based Diagnosis of Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P13.	0.4	0
257	P2â€142: Comparison of Tâ€Tau, Neurogranin and NFL as CSF Neurodegeneration Markers in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P667.	0.4	0
258	[O2â€"05â€"05]: EFFECTS OF <i>APOE</i> E4 IN PRODROMAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P562.	0.4	0
259	[P3â€"132]: CSF BIOMARKERS OF NEUROINFLAMMATION ARE ELEVATED IN PRECLINICAL AND PRODROMAL AD AND CORRELATE WITH TAU PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P985.	0.4	0
260	[P4â€"197]: EMERGING AMYLOID PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P1340.	0.4	0
261	[P1â€"575]: PREVALENCE OF THE APOLIPOPROTEIN E Îµ4 ALLELE IN AMYLOIDâ€Î² POSITIVE SUBJECTS ACROSS THE SPECTRUM OF ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P515.	0.4	0
262	[P3â€"075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS. Alzheimer's and Dementia, 2017, 13, P960.	0.4	0
263	P1â€279: BIMODAL DISTRIBUTION OF THE CSF AÎ²42/AÎ²40 RATIO IN CLINICAL LABORATORY PRACTICE. Alzheimer's and Dementia, 2018, 14, P389.	0.4	0
264	DTâ€01â€06: COGNITIVE DECLINE IN PRECLINICAL ALZHEIMER'S DISEASE: A COMPARISON AND SYNTHESIS OF LARGE INTERNATIONAL COHORTS. Alzheimer's and Dementia, 2018, 14, P1667.	0.4	0
265	P1â€430: EFFECTS OF <i>APOE</i> Îµ4 ON TAU, AMYLOID, ATROPHY AND COGNITION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P473.	0.4	0
266	DTâ€01â€01: DEVELOPMENT OF AB, TAU AND COGNITIVE CHANGES DURING THE TIME COURSE OF SPORADIC ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1665.	0.4	0
267	Primary fatty amides are potential plasma biomarkers for AD. Nature Reviews Neurology, 2019, 15, 498-499.	4.9	0
268	P4â€536: CEREBROSPINAL FLUID BIOMARKERS FOR AMYLOID AND TAU USING FULLY AUTOMATED ASSAYS: ASSOCIATIONS WITH NEUROPATHOLOGY. Alzheimer's and Dementia, 2019, 15, P1521.	0.4	0
269	DTâ€01â€04: DIAGNOSTIC PERFORMANCE OF [¹⁸F]RO948 PET IN THE SEPARATION OF ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDERâ€2 STUDY. Alzheimer's and Dementia, 2019, 15, P1485.	0.4	0
270	Comparison of 18 Fâ€Flortaucipir visual assessment, SUVR quantification and CSF pTau for defining Tâ€status in the AT(N) framework. Alzheimer's and Dementia, 2020, 16, e037276.	0.4	0

#	Article	IF	Citations
271	Cerebrospinal Fluid Biomarkers in Alzheimerâ€™s Disease and Frontotemporal Dementia. , 2014, , 131-157.		0
272	A new member in the biomarker discovery toolbox. Biomarkers in Medicine, 2011, 5, 202.	0.6	0
273	Troponin T: more than acute myocardial infarction. Biomarkers in Medicine, 2011, 5, 203.	0.6	0
274	Growth factors in Parkinson's disease. Biomarkers in Medicine, 2011, 5, 201-2.	0.6	0
275	It is all about clearance. Biomarkers in Medicine, 2011, 5, 202.	0.6	0
276	Ability of tauâ€PET, phosphoâ€tau217, NfL and cortical thickness to predict shortâ€term cognitive decline in early symptomatic Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
277	Unravelling drivers of ageâ€and betaâ€amyloidâ€related neurodegeneration in medial temporal lobe atrophy in cognitively normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
278	Plasma biomarkers predict longitudinal amyloid accumulation, tau burden, brain atrophy and cognitive decline in early Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
279	Comparing the clinical utility and diagnostic performance of cerebrospinal fluid Pâ€tau181, Pâ€tau217 and Pâ€tau231 assays. Alzheimer's and Dementia, 2021, 17, .	0.4	0
280	Amyloidâ€Î² accumulation is independently related to executive function in cognitively unimpaired adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
281	Potential drivers of ageâ€and betaâ€amyloidâ€related neurodegeneration in early and late Alzheimerâ€™s Disease regions in cognitively normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
282	Genetic influence during the early phases of Alzheimer's disease on longitudinal cognitive impairment.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e053474.	0.4	0
283	Genetic interaction study of Alzheimer's disease quantitative biomarkers: A polygenic risk score analysis and evaluation.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e053556.	0.4	0